146 related articles for article (PubMed ID: 16020974)
1. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Palmeri S; Vaglica M; Spada S; Filippelli G; Farris A; Palmeri L; Massidda B; Misino A; Ferraù F; Comella G; Leonardi V; Condemi G; Mangiameli A; De Cataldis G; Macaluso MC; Cajozzo M; Iannitto E; Danova M
Oncology; 2005; 68(4-6):438-45. PubMed ID: 16020974
[TBL] [Abstract][Full Text] [Related]
2. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Joensuu H; Sailas L; Alanko T; Sunela K; Huuhtanen R; Utriainen M; Kokko R; Bono P; Wigren T; Pyrhönen S; Turpeenniemi-Hujanen T; Asola R; Leinonen M; Hahka-Kemppinen M; Kellokumpu-Lehtinen P
Ann Oncol; 2010 May; 21(5):968-73. PubMed ID: 19819914
[TBL] [Abstract][Full Text] [Related]
6. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
7. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
[TBL] [Abstract][Full Text] [Related]
8. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Halim A; Wahba H
Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
[TBL] [Abstract][Full Text] [Related]
9. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Hausmaninger H; Morack G; Heinrich B; Wallwiener D; Höffken K; Buksmaui S; Krejcy K; Miller MA; Possinger K
Am J Clin Oncol; 2004 Aug; 27(4):429-35. PubMed ID: 15289740
[TBL] [Abstract][Full Text] [Related]
11. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
14. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
Gómez-Bernal A; Cruz JJ; García-Palomo A; Arizcun A; Pujol E; Diz P; Martín G; Fonseca E; Sánchez P; Rodríguez C; del Barco E; López Y
Am J Clin Oncol; 2003 Apr; 26(2):127-31. PubMed ID: 12714881
[TBL] [Abstract][Full Text] [Related]
15. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
[TBL] [Abstract][Full Text] [Related]
18. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and docetaxel in metastatic breast cancer.
Seidman AD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):13-6. PubMed ID: 15685820
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Pelegrí A; Calvo L; Antón A; Mayordomo JI; Florián J; Vásquez S; Arcusa A; Martín-Richard M; Bayo JL; Carrasco E; Virizuela J;
Clin Breast Cancer; 2005 Dec; 6(5):433-8. PubMed ID: 16381627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
